Roche buys US Foundation Medicine for $2.4 bn

Geneva: Swiss pharmaceutical giant Roche said Tuesday it had reached an agreement to purchase the remaining shares of US lab Foundation Medicine, of which it already holds a majority stake, for $2.4 billion.

Roche said it had agreed to pay shareholders in the US company, which is specialised in molecular analysis and genomic profiling aimed at transforming cancer care, $137 per share.

This represents a 29-percent premium on the closing price for Foundation Medicine (FMI) Monday evening and a 68-percent premium on the company’s 90-day weighted average share price, Roche said.

The overall transaction thus amounts to $2.4 billion, with FMI, of which Roche already held a 57-percent stake, valued at $5.3 billion, the statement said.

The boards of both companies have unanimously approved the merger agreement.

Roche, the world’s top cancer drug maker, said it aimed to close the deal by the end of the year.

“This is important to our personalised healthcare strategy,” said Daniel O’Day, head of Roche’s pharmaceutical unit.

“We believe molecular insights and the broad availability of high quality comprehensive genomic profiling are key enablers for the development of, and access to, new cancer treatments,” he said in the statement.

FMI, which is based in Cambridge, Massachusetts, will continue to function as an autonomous entity, he said.

Analysts hailed the deal, with Stefan Schneider of Vontebel saying it “fit very well with Roche’s personalised healthcare strategy.”

He pointed out in an investment note that the Swiss company was an “early leader in the field”.

Investors too appeared pleased with the move.

Following the announcement, Roche saw its share price rise 0.79 percent in midday trading to 211.65 Swiss francs a piece, as the Swiss stock exchange’s main SMI index slipped 0.66 percent.

  • Related Posts

    • Pharma
    • December 23, 2024
    • 43 views
    Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

    India’s healthcare and pharmaceutical sectors raised Rs 14,811 crore through initial public offerings (IPOs) in 2024, the largest since 2019, driven by strong domestic demand amid expanding global opportunities. According…

    • Pharma
    • December 23, 2024
    • 52 views
    NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

    The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 65 new drug formulations and notified ceiling price fixation of 13 formulations. The regulatory body, under the Department of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

    Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

    NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

    NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

    India-Latin America trade and collaboration prospects discussed at Kerala University conference

    India-Latin America trade and collaboration prospects discussed at Kerala University conference

    Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

    Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

    NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

    NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

    Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt

    Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt